Uncategorized

Drug Development Quiz

Drug Development Quiz Answer. In this post you will get Quiz Answer Of Drug Development

 

Drug Development Quiz

Offered By ”University of California San Diego”

Enroll Now

Week- 1

Regulatory Considerations When Filing an Investigational New Drug Application Quiz

 

1.
Question 1
An Investigational New Drug (IND) is not required for which of the following?

1 point

  • Studies examining a new route of administration
  • Initiation of clinical studies on a new drug
  • Marketed drugs where the study would use approved doses
  • Studies examining a different indication

2.
Question 2
When an Investigational New Drug (IND) application is “in effect” what does it permit a sponsor to do?

1 point

  • Begin studies in animals
  • Set the price of the drug
  • Begin studies in humans
  • Market the drug

3.
Question 3
Which of the following is a FALSE statement regarding IND safety reporting?

1 point

  • For a fatal or life threatening AE, 1 calendar day to report
  • For a serious or unexpected AE, written notification must be sent to the FDA and investigators
  • For a serious or unexpected AE, 15 calendar days to report
  • For a fatal or life threatening AE, must notify FDA via phone or fax

4.
Question 4
Which kind of drugs take comparatively longer time to develop?

1 point

  • Biologics
  • Small molecular entities
  • Oncolytics

5.
Question 5
According to the lecture, how many drugs reach the pre-clinical stage if a company starts with ~5,000-10,000 lead compounds in pre-discovery stage?

1 point

  • 50
  • 250
  • 1,000
  • 8,000

6.
Question 6
Which countries in the EU have more stringent and scientifically rigorous rules to go through to get approved by EMA? (Choose 2)

1 point

  • Germany
  • France
  • Italy
  • Sweden

7.
Question 7
What can be the potential decisions of an IND review? (Choose 2)

1 point

  • IND may not get approved by FDA
  • Clinical hold may be put on IND at any point of time
  • IND is ‘in effect’ on day 21 if no negative comments are received from FDA

 

 

Clinical Study & Start-up Activities Quiz

1.
Question 1
You have developed inclusion/exclusion (I/E) criteria for a clinical study. Subject enrollment is slow. Based on regulatory guidelines, are you allowed to revise I/E criteria during the course of the study?

1 point

Yes, you can revise I/E criteria

No, you are not allowed to revise I/E criteria

2.
Question 2
All of the following are required elements of the informed consent form (ICF) EXCEPT:

1 point

Potential risks and benefits

Statistical method used in study

Information about how a drug works

Study purpose

3.
Question 3
All of the following are required elements of a protocol EXCEPT:

1 point

Identifying study objectives

Requirements to be the study’s primary investigator

Background of target rationale

Defining study inclusion/exclusion criteria

4.
Question 4
Which of the following are described as the key objectives of a Phase I trial, regardless of drug?

1 point

assess appropriateness of stopping rules

determine inclusion/exclusion recommendations

characterize the pharmacokinetic (PK) profile

assess safety and tolerability

5.
Question 5
What does FIH stand for?

1 point

Foundational Institute of Health

Fast in Host

First in Human

6.
Question 6
Which of the following are the 3 MOST important to look at when considering our inclusion/exclusion criteria?

1 point

The potential side-effect profile

The potential for drug abuse

The mechanism of the drug

The potential for drug interaction

7.
Question 7
True or False: It is required to have an IND before your Phase 1 trial

1 point

False

True

 

 

Week- 2

Clinical Trials: Phase 1 Quiz

 

1.
Question 1
Drug X is an investigational agent for high blood pressure. Which of the following study designs would be appropriate for a first in human (FIH) Phase 1 study?

1 point

A placebo-controlled, single dose in healthy adults

An open-label, single dose in patients with high blood pressure

A placebo-controlled, multiple dose in healthy adults

An open-label, multiple-dose in patients with high blood pressure

2.
Question 2
Which pharmacokinetic parameter will allow you to determine drug exposure?

1 point

t1/2 (elimination half-life)

AUC (area under the concentration versus time curve)

Tmax (time to maximum concentration)

CL (plasma clearance)

3.
Question 3
What is the primary objective of a phase I study?

1 point

To determine biologic activity of a drug

To determine drug manufacturing needs

To determine drug efficacy

To determine drug safety and tolerability

4.
Question 4
Which three people were mentioned as those likely to get together to identify a starting dosage level?

1 point

the FDA expert

the toxicologist

the clinical scientist

the pharmacokinetics scientist

5.
Question 5
Normally first-in-human studies are conducted in healthy volunteers except (choose 2)

1 point

mentally challenged patients

HIV patients

oncology patients

6.
Question 6
Which of the following was described as the easiest and most important changes that could have improved the Tegenero Phase 1 study?

1 point

staggering timing of dosage

changing the starting dosage

being close to an ICU

changing the study design

 

 

Clinical Trials: Phase 2 Quiz

1.
Question 1
What is the primary objective of a Phase 2b study?

1 point

Determine a drug’s safety and tolerability profile

Determine drug pharmacokinetics

Establish drug dose ranges for subsequent studies

To establish bioequivalence of a drug

2.
Question 2
What would be the most optimal drug to develop based on the therapeutic index?

1 point

Drug with a therapeutic index ratio of greater than 10

Drug with a narrow therapeutic index

Drug with a therapeutic index ratio equal to zero

Drug with a therapeutic index ratio less than 1

3.
Question 3
Which of the following outcome from a phase 2 trial would result in continuation to phase 3?

1 point

Discovery of an irreversible, serious adverse event

Establishing the therapeutic dose of a drug

Placebo providing statistically significant efficacy

Determining therapeutic dose to be 50 grams

4.
Question 4
Which were two of the things in Phase 2 trials that contribute to greater confidence in your compound

1 point

simulation

mathematical modelling

therapeutic index

use in humans

5.
Question 5
What is illustrated by the difference between the therapeutic effect and the toxic effect (as pointed at by the blue arrow)?

1 point

Therapeutic index

Efficacy plateau

Dosage rate

Hill curve

 

 

Week- 3

Industry Considerations with Phase III Clinical Trials Quiz

 

1.
Question 1
All of the following are design features of a Phase 3 study EXCEPT?

1 point

Multi-center sites

Open-label study

Large sample size

Performance in final dosage form

2.
Question 2
All of the following are common causes of study delays EXCEPT:

1 point

Legal Review

Earlier safety data

Patient recruitment

Marketing authorization

3.
Question 3
Which of the follow were stated as benefits of medical research? (Choose 3)

1 point

Development of approximate costs for future clinical studies

Reduction in total burden of chronic disease

Impact on disease prevention

Informational changes to pharmaceutical research

4.
Question 4
Historically drug commercialization was more ________ and today it is more _________.

1 point

global, US-driven

US-driven, global

linear, parallel

parallel, linear

5.
Question 5
The current estimate of the cost of the full drug development cycle was stated as being in which range/

1 point

< 500 million

500 million to 1 billion

1-1.5 billion

1.5-2 billion

6.
Question 6
Considerations of effect on varying populations usually occurs in what stage trial/

1 point

2

3

4

7.
Question 7
Why is stage 3 study design and execution so important?

1 point

Evaluation of Efficacy

Assurance of Safety

Ability to Commercialize

 

 

New Drug Application, Filing, Product Labeling Quiz

 

1.
Question 1
All of the following are required for a U.S. FDA New Drug Application EXCEPT:

1 point

Preclinical data

Packaging methods

Disclosure of intent to file in other countries

Human bioavailability

2.
Question 2
All of the following are examples of post-marketing studies EXCEPT:

1 point

Proof of principle study

Studies of new uses of drug

Safety surveillance study

Study examining effectiveness in widespread populations

3.
Question 3
True or False: When a new drug application is submitted by company X, that is public to company Y.

1 point

True

False

4.
Question 4
The two characteristics required for fast track approvals are which?

1 point

treats a serious illness

fills an unmet need

an advance on existing treatment

5.
Question 5
Increased in interest in pharmacoeconomic data was described as coming from where?

1 point

pharmaceutical companies wanting to build better models to guide drug development

the FDA looking to prioritize future application processing

insurance companies wanting to determine if there would be a cheaper standard of care

 

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *